New Formulation of Jetrea Approved
June 8, 2016 – The U.S. Food and Drug Administration (FDA) approved a new formulation of Jetrea® (ocriplasmin) for the treatment of vitreomacular adhesion (VMA). Jetrea is manufactured by ThromboGenics NV. While Jetrea is already approved, the new formulation will come as an already-diluted version, eliminating the previously required preparatory dilution steps prior to injection. Jetrea is administered by intravitreal (eye) injection as a one-time dose. It is the only pharmacological treatment approved for treatment of VMA.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.